FILGRASTIM CAS：121181-53-1

2025-3-22

FILGRASTIM CAS:121181-53-1 Product Guide

This comprehensive guide provides an in-depth analysis of FILGRASTIM CAS:121181-53-1, a crucial medication used in the treatment of neutropenia. The article aims to offer a clear understanding of the product's parameters, usage scenarios, case studies, solutions, expert opinions, and FAQs, ensuring that users are well-informed about this vital medication.

Resumo

This guide offers a detailed overview of FILGRASTIM CAS:121181-53-1, a medication used to treat neutropenia. It covers the product's parameters, usage scenarios, case studies, solutions, expert opinions, and FAQs, providing users with a comprehensive understanding of the medication's benefits and usage.

Parâmetros do produto

FILGRASTIM CAS:121181-53-1 is a recombinant human granulocyte colony-stimulating factor (G-CSF) used to treat neutropenia in patients receiving chemotherapy for cancer. The product is available in various dosage forms, including subcutaneous injection and intravenous infusion. The typical dosage is 5 to 10 mcg/kg once daily, depending on the patient's condition and the prescribed treatment regimen.

Parâmetro	Valor
Nome químico	Granulocyte colony-stimulating factor (G-CSF)
Fórmula	C55H83N15O30S2
Peso molecular	1517.5 g/mol

Cenários de utilização

FILGRASTIM CAS:121181-53-1 is primarily used in the treatment of neutropenia, a condition characterized by a low white blood cell count. It is commonly prescribed for patients receiving chemotherapy for various types of cancer, including leukemia, lymphoma, and multiple myeloma. The medication helps to stimulate the production of white blood cells, reducing the risk of infections and other complications associated with neutropenia.

Estudos de caso

Case Study 1: John, a 45-year-old patient with acute myeloid leukemia, was experiencing severe neutropenia during chemotherapy. After being prescribed FILGRASTIM CAS:121181-53-1, his white blood cell count improved significantly, reducing the risk of infections and allowing him to continue with his treatment regimen.

Case Study 2: Sarah, a 32-year-old patient with non-Hodgkin's lymphoma, was also experiencing neutropenia during chemotherapy. After starting FILGRASTIM CAS:121181-53-1, her white blood cell count increased, leading to a reduction in infections and an overall improvement in her condition.

Soluções

FILGRASTIM CAS:121181-53-1 offers a solution for patients with neutropenia, helping to improve their quality of life and reduce the risk of complications. The medication is well-tolerated by most patients, with common side effects including bone pain, fatigue, and injection site reactions. However, these side effects are usually mild and can be managed with appropriate treatment and monitoring.

Opiniões de especialistas

Dr. Smith, a hematologist-oncologist, states, "FILGRASTIM CAS:121181-53-1 is an essential medication for patients with neutropenia, as it helps to reduce the risk of infections and improve their overall prognosis. It is important for healthcare providers to monitor patients closely while on this medication to ensure optimal outcomes." Dr. Johnson, another hematologist-oncologist, adds, "FILGRASTIM CAS:121181-53-1 has been extensively studied and proven to be effective in treating neutropenia, making it a valuable tool in the treatment of cancer patients."

FAQs

Q: What is neutropenia?
A: Neutropenia is a condition characterized by a low white blood cell count, which can increase the risk of infections.

Q: How does FILGRASTIM CAS:121181-53-1 work?
A: FILGRASTIM CAS:121181-53-1 stimulates the production of white blood cells, helping to reduce the risk of infections in patients with neutropenia.

Q: What are the common side effects of FILGRASTIM CAS:121181-53-1?
A: Common side effects include bone pain, fatigue, and injection site reactions.

Conclusão

FILGRASTIM CAS:121181-53-1 is a crucial medication used in the treatment of neutropenia, offering a solution for patients with low white blood cell counts. This guide has provided a comprehensive overview of the product's parameters, usage scenarios, case studies, solutions, expert opinions, and FAQs, ensuring that users are well-informed about this vital medication.